Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Acta Myol ; 32(2): 100-5, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-24399867

RESUMEN

Patients with muscle pathology are a challenge for anaesthesiologists because of possible life-threatening general anaesthesia complications. A review of the current medical literature on the issue clearly indicates that increasing awareness by anaesthesiologists in recent years has led to a reduction in the occurrence of adverse events in patients with diagnostically well-defined muscle disease. On the other hand, the current emerging aspect is that the great majority of complications concern subjects with clinically non-overt (silent to mildly symptomatic) and thus undiagnosed myopathy. With a view to improving prevention of possible critical anaesthesia complications in such patients, we present a "Safe Anaesthesia Table", listing both the anaesthetic drugs to be avoided and those considered harmless for myopathic patients, irrespective of age and type of pathology. In addition, a brief outline about the clinical aspects suggestive of a possible muscle pathology is also provided. Using "safe drugs" during routine surgical procedures in subjects with suspected undiagnosed myopathy will enable the anaesthesiologist to avoid delaying surgery, while protecting them from anaesthesia complications. By following this approach the presumed myopathy can be properly investigated after surgery.


Asunto(s)
Anestésicos , Errores Diagnósticos/prevención & control , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Enfermedades Musculares , Adulto , Anestesia/métodos , Anestésicos/administración & dosificación , Anestésicos/efectos adversos , Anestésicos/clasificación , Enfermedades Asintomáticas , Niño , Contraindicaciones , Monitoreo de Drogas/métodos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/clasificación , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/etiología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/fisiopatología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/prevención & control , Humanos , Enfermedades Musculares/complicaciones , Enfermedades Musculares/diagnóstico , Enfermedades Musculares/fisiopatología , Daño del Paciente/prevención & control , Cuidados Preoperatorios/métodos
2.
In Vivo ; 20(6A): 703-6, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-17203749

RESUMEN

Peritoneal carcinomatosis has always been regarded as a contraindication in traditional cancer surgery treatment; however, good results have been reported by using new combined medical-surgical loco-regional techniques. Peritonectomy and chemohyperthermic perfusion with cisplatinum (CIIP) seem to play a central role in obtaining a better survival rate than with the traditional procedures, even though there is a cisplatinum nephrotoxic effect. The aim of this study was to investigate entity and type of renal injury after CIIP. Forty-two patients (12 males and 30 females) with recurrent or primary peritoneal carcinomatosis who underwent peritonectomy and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy with cisplatin were enrolled. A significant worsening in renal function was observed on the third post-operative day and this condition then persisted for three months. A reduction in estimated-Glomerular Filtration Rate (e-GFR) and an alteration in the albumin:creatinine ratio proved tubular injury. On the third post-operative day after cisplatinum administration, a high toxicity peak was found following platinum free fraction excretion. Proximal tubular injury was confirmed even at the three month analysis. A significant correlation between the total protein reduction rate and the decrease in renal function was established. In relation to that, the platinum free fraction could increase because of a binding protein shortage and the nephrotoxic effect could be enhanced due to platinum accumulation within the post-operative period. This finding suggests that the higher the protein reduction is, the lower the e-GFR determination is at three months.


Asunto(s)
Antineoplásicos/efectos adversos , Carcinoma/terapia , Cisplatino/efectos adversos , Enfermedades Renales/inducido químicamente , Túbulos Renales/efectos de los fármacos , Neoplasias Peritoneales/tratamiento farmacológico , Peritoneo/cirugía , Albuminuria/diagnóstico , Albuminuria/orina , Quimioterapia del Cáncer por Perfusión Regional , Terapia Combinada , Creatina/orina , Femenino , Tasa de Filtración Glomerular/efectos de los fármacos , Humanos , Hipertermia Inducida , Enfermedades Renales/metabolismo , Enfermedades Renales/fisiopatología , Túbulos Renales/metabolismo , Túbulos Renales/fisiopatología , Masculino , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda